Eliem Therapeutics Q1 net loss $22.3M; cash $109.4M funds operations into 2027

Climb Bio, Inc.

2023-Q1 EPS reported -$0.84

Net loss of $22.3M for Q1 2023 vs $13.2M in Q1 2022; includes $15.8M restructuring costs.
Cash, cash equivalents and marketable securities $109.4M as of March 31, 2023.
Presented initial preclinical data for lead Kv7 candidate ETX-123; IND-enabling studies initiated.
Phase 1 clinical studies for ETX-123 planned to start in first half of 2024.
R&D expenses $5.7M, G&A expenses $17.7M (includes $14.0M restructuring costs).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Climb Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $22.3 million.

Period: the quarter ended March 31, 2023
Net income: Net loss was $22.3 million
Result: reported results

Exact text from the filing

Eliem Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021244

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.